Brought to you by 
Daiichi pays AZ $200mm up front to co-promote Movantik in the US; deal ends as rights transfer to RedHill
27 Feb 2020
Executive Summary
AstraZeneca PLC chose Daiichi Sankyo Inc. to co-promote the newly approved constipation therapy Movantik (naloxegol) in the US. Daiichi paid $200mm in cash up front, and could hand over up to $625mm in sales-based milestones.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daiichi pays AZ $200mm up front to co-promote Movantik in the US; deal ends as rights transfer to RedHill
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice